◆英語タイトル:Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013470
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a research and development company that develops and delivers RNA interference therapeutics for the treatment of serious diseases. The company’s pipeline products include Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer. Silence Therapeutics offers Atu111 for lung indications. The company also develops other products which include PF-655 for diabetic macular edema and wet age related macular degeneration; and QPI 1002 for kidney transplantation and acute kidney injury. It has collaboration with pharmaceutical, biotechnology companies and academic research institutions. The company has presence in Berlin, Germany. Silence Therapeutics is headquartered in London, the UK.
Silence Therapeutics Plc (SLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Silence Therapeutics Enters into Agreement with MiReven 11
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 12
Silence Therapeutics Enters into Agreement with miRagen Therapeutics 13
Equity Offering 14
Silence Therapeutics Raises USD59 Million in Private Placement of Shares 14
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 15
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 16
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 17
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 19
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 20
Silence Therapeutics Completes Private Placement Of US$9 Million 21
Silence Therapeutics Completes Public Offering Of US$0.71 Million 23
Acquisition 24
Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 24
Silence Therapeutics Plc – Key Competitors 25
Silence Therapeutics Plc – Key Employees 26
Silence Therapeutics Plc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Sep 06, 2017: Silence Therapeutics: Interim results for the six months ended 30 June 2017 28
Mar 28, 2017: Silence Therapeutics: Preliminary results for the year to 31 December 2016 29
Sep 27, 2016: Silence Therapeutics: Interim results for the six months ended 30 June 2016 31
Sep 27, 2016: Silence Therapeutics Announces Interim results for the six months ended 30 June 2016 32
Apr 05, 2016: Silence Therapeutics: Preliminary results for the year to 31 December 2015 33
Corporate Communications 34
Oct 16, 2017: Appointment of Dr. Annalisa Jenkins, MBBS, FRCP as Non-Executive Chair 34
Jul 14, 2017: Silence CEO, Ali Mortazavi, appointed Chairman of Ultromics 35
Sep 05, 2016: Silence Therapeutics appoints Dmitry Samarsky, PhD as Chief Scientific Officer and Dr Andy Richards CBE as Non-Executive Director 36
May 24, 2016: Silence Therapeutics Announces Management Changes 38
Legal and Regulatory 39
Nov 20, 2017: Silence Therapeutics: Update on litigation matters 39
Nov 03, 2017: Silence Therapeutics: Update on litigation matters 40
Oct 17, 2017: Silence Therapeutics: Serving of claim in the UK High Court 41
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 42
Dec 20, 2016: Quark arbitration resolution 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List of Tables
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Silence Therapeutics Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Silence Therapeutics Enters into Agreement with MiReven 11
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 12
Silence Therapeutics Enters into Agreement with miRagen Therapeutics 13
Silence Therapeutics Raises USD59 Million in Private Placement of Shares 14
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 15
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 16
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 17
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 19
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 20
Silence Therapeutics Completes Private Placement Of US$9 Million 21
Silence Therapeutics Completes Public Offering Of US$0.71 Million 23
Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 24
Silence Therapeutics Plc, Key Competitors 25
Silence Therapeutics Plc, Key Employees 26
Silence Therapeutics Plc, Subsidiaries 27